# A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct06084884/  
OnCo record `nct06084884` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD5851 in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT06084884 by AstraZeneca, with 94 participants enrolled, started 2023-12-14 and due to reach its primary completion in 2027-12-13. Interventions recorded: AZD5851.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06084884
- Phase: 1/2
- Setting: A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA
- Sponsor: AstraZeneca
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT06084884: https://clinicaltrials.gov/study/NCT06084884

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06084884.json